# Quotient Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/quotient-therapeutics

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.quotient-tx.com
- Total disclosed funding: $50M
- Latest round: Series A (Nov 20, 2023)
- Investors on record: 1

## About

Based in London, UK, and founded in 2021, Quotient Therapeutics Limited is a biotechnology research company that focuses on the study of genetic variation at the cellular level to discover therapeutics informed by new links between genes and diseases. The company was co-founded by Jake Rubens (President). As of 2023, the company is led by Geoffrey Maltzahn (CEO). In November 2023, new investor Flagship Pioneering led USD 50 million in Series A funding for Quotient Therapeutics Limited.

Quotient Therapeutics is developing a somatic genome platform to detect genetic variations that may contribute to diseases occurring within an individual. This initiative aims to create groundbreaking therapies for a range of conditions, including immune disease, cardiometabolic disease, infectious disease, oncology, neurodegenerative disease, rare disease, and ageing. 

The company plans to use the November 2023 funding to further develop its platform and ramp up a pipeline of medicines.

## Funding rounds

- Series A, Nov 20, 2023, $50M — Flagship Pioneering

## Investors

- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A